Kolexia
Wislez Marie Pneumologie
Wislez Marie
Pneumologie
Hôpital Cochin
Paris, France
869 Activités
1.2 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Carcinomes Adénocarcinome Adénocarcinome pulmonaire Métastase tumorale Maladies pulmonaires Lymphomes

Collaborateurs

Voir plus
Cadranel Jacques
Cadranel Jacques
Hôpital Tenon, Paris, France
Antoine Martine
Antoine Martine
Hôpital Tenon, Paris, France
Lavole Armelle
Lavole Armelle
Hôpital Tenon, Paris, France
Mazieres Julien
Mazieres Julien
Hôpital Rangueil, Toulouse, France

Industries

Voir plus
AstraZeneca
43 collaboration(s)
Dernière en 2023
MSD
37 collaboration(s)
Dernière en 2022
Lilly
23 collaboration(s)
Dernière en 2023
Amgen
18 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3): Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Essai Clinique (BMS)   11 mars 2024
Resected -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).
Therapeutic advances in medical oncology   06 mars 2024
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK): A Phase II Randomized, Open-Labelled, Multicenter Study of Safety & Efficacy of Combination Brigatinib and Carboplatin-Pemetrexed Therapy or Brigatinib Monotherapy as First-Line Treatment in Advanced ALK-Positive Non-Small Cell Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
ROSIE: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Essai Clinique (Loxo Oncology, Inc.)   27 février 2024
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Essai Clinique (Unicancer)   26 février 2024
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Lung cancer (Amsterdam, Netherlands)   19 février 2024
PNN-CP: Studies of Phenotypic and Functional Characteristics of Circulating Neutrophil Subpopulations in Patients With Lung Cancer Undergoing Treatment
Essai Clinique (Assistance publique – Hôpitaux de Paris)   05 février 2024
PACT-01: Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
Essai Clinique (Institut Curie)   29 janvier 2024
A 2023 inventory in oncology news.
Bulletin du cancer   05 janvier 2024